Chemical‐Driven Clearance of Aβ and tau Aggregates by Orally Available Small Molecule Drug Candidate AS‐S603

AS-S603 is a first-in-class oral treatment for AD, uniquely targeting both Aβ and tau aggregates. It provides significant cognitive benefits in preclinical studies, suggesting its potential to alter disease progression. Clinical studies will validate its safety and efficacy, positioning AS-S603 as a transformative treatment for AD.